0908 GMT - Innovent Biologics' near-term stock performance may depend on the approval and sales of its potential blockbuster drug Mazdutide in 1H2025, according to Deutsche Bank Research analyst Cyrus Ng in a commentary. The biotech company's share price has rebounded 14% since January 25, outperforming its peers' average of 4.9% during the same period, Ng says. However, revenue growth slowed in Q4 compared to the previous quarter, although 2024 product sales remain in line with expectations, the analyst notes. Ng maintains a buy rating and a target price of HK$49.00. Shares were last up 0.3% at HK$36.35. (tracy.qu@wsj.com)
(END) Dow Jones Newswires
February 10, 2025 04:08 ET (09:08 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。